Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation - Wikidata - awgldk - TriplyDB

Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation

Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation

http://www.wikidata.org/entity/Q36907832

about

Molecular and Cellular Mechanisms of Myelodysplastic Syndrome: Implications on Targeted Therapy Acute Myeloid Leukemia: A Concise Review Progress in acute myeloid leukemia FLT3 mutations in acute myeloid leukemia: what is the best approach in 2013?Novel therapeutic options in Acute Myeloid Leukemia 'Acute myeloid leukemia: a comprehensive review and 2016 update'DNMT3A and TET2 in the Pre-Leukemic Phase of Hematopoietic Disorders Novel Prognostic and Therapeutic Mutations in Acute Myeloid Leukemia Secondary mutations as mediators of resistance to targeted therapy in leukemia Advancements in the delivery of epigenetic drugs Ligand-target prediction by structural network biology using nAnnoLyze Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study.Emerging therapies for acute myeloid leukemia.Tyrosine kinase inhibitors targeting FLT3 in the treatment of acute myeloid leukemia.Relapsed acute myeloid leukemia: why is there no standard of care?Antineoplastic effects of CPPTL via the ROS/JNK pathway in acute myeloid leukemia.Targeted therapies in hematology and their impact on patient care: chronic and acute myeloid leukemia.Molecular therapy for acute myeloid leukaemia.Investigational FMS-like tyrosine kinase 3 inhibitors in treatment of acute myeloid leukemia Sorafenib is tolerable and improves clinical outcomes in patients with FLT3-ITD acute myeloid leukemia prior to stem cell transplant and after relapse post-transplant Gene mutation patterns in patients with minimally differentiated acute myeloid leukemia.The Future of Targeting FLT3 Activation in AML.Phase I trial of maintenance sorafenib after allogeneic hematopoietic stem cell transplantation for fms-like tyrosine kinase 3 internal tandem duplication acute myeloid leukemia.Acute myeloblastic leukaemias in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.Improving outcomes for patients with acute myeloid leukemia in first relapse: a single center experience Small molecule inhibitors in acute myeloid leukemia: from the bench to the clinic Phase I/II trial of the combination of midostaurin (PKC412) and 5-azacytidine for patients with acute myeloid leukemia and myelodysplastic syndrome.Rational Combinations of Targeted Agents in AML Targeted Therapy of FLT3 in Treatment of AML-Current Status and Future Directions.A phase I study of midostaurin and azacitidine in relapsed and elderly AML patients International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts.Improvement in clinical outcome of FLT3 ITD mutated acute myeloid leukemia patients over the last one and a half decade.Inefficiencies and Patient Burdens in the Development of the Targeted Cancer Drug Sorafenib: A Systematic Review Profiling of somatic mutations in acute myeloid leukemia with FLT3-ITD at diagnosis and relapse.Is targeted therapy feasible in acute myelogenous leukemia?Recent advances and novel agents for FLT3 mutated acute myeloid leukemia.Acute myeloid leukemia: advancing clinical trials and promising therapeutics.Economic impact of genomic diagnostics for intermediate-risk acute myeloid leukaemia Hypomethylating agents after allogeneic blood stem cell transplantation.How I treat FLT3-mutated AML.

P2860

Q26749870-13396C8F-5820-4139-8B0B-6F39BF898700 Q26766719-D22D3005-3586-4E9F-82CE-9590AE44B7F0 Q27024006-48F23B92-D16A-4659-A32E-A4B55A942FAA Q27028163-77F508B8-7016-40CC-BB07-D3B83D3B2C7C Q28069889-7D499884-E02A-45D3-8BEA-8736EE8EE524 Q28072539-E1683B66-1838-4B82-A117-A9C692C26109 Q28073970-998501C8-7587-4FC9-A060-9CC64635D645 Q28075654-BD0AF653-633F-4FBE-89A1-DB2C194BEA33 Q28087213-4EE9F5CD-3A3D-4041-939D-B3BE7D1F990A Q28088478-4BFBC08B-E50F-42A1-8550-718219C6396A Q28545126-A1089DDF-5840-4DEE-B9A1-A69A84D6C61E Q33442949-94F25869-532C-4C91-8A95-A38CF8AD11BD Q33576363-445E61DD-0EF7-45ED-8305-1E0E430271B1 Q33767026-EFB55169-34FB-4597-A98C-C6344E2028C5 Q33877202-23180C79-067D-4AFF-A435-FF74A28BE9A1 Q33889046-06584EC2-F3C2-41CC-A350-C335D1BBD102 Q33903030-2749CAF6-5BF6-425E-BD96-1A6C697C3307 Q33925672-43BAD9D4-26A3-496B-828C-AF9A606071DA Q33943277-DC4EA895-5CDA-4BA7-8A0F-DEF6B0106703 Q34088370-85475720-A975-4965-A5E9-DF3F88A696CC Q34347096-B82D73B0-9218-479A-BD01-FD9614EC688D Q34555386-E58F3AA2-86D9-4687-85ED-7CFE7CB6662C Q34620695-83F451A4-764D-40CB-AD70-2CDE90265B5D Q34655572-7B517259-1DC5-4F34-A91A-9421E6B61A9F Q34772229-DE5192EC-180F-4AE7-ADAF-056633600A76 Q34817365-0C2C0CA9-05AD-4806-A54E-AE2EB226BD49 Q35224437-6239A398-6671-464B-8CBA-D5B8EB68D3D0 Q35750491-7AED26B8-6650-41A6-842C-85D1D441562A Q35750567-C426E5B0-7309-431E-861C-102ED1A1E07E Q35793176-267C2830-72E8-4C1D-9897-F4A3D8F56561 Q35859212-55D0128D-CE4D-4DC6-9F25-B8477A2C59BC Q36200300-9E858145-47EC-4331-8AC4-5034F098DD81 Q36270115-D2C40626-6807-40B9-BC92-760DA65826C2 Q36322776-27513233-5E62-404C-B2EE-73E130FEDC55 Q36416358-E5DD1AEA-713B-4189-B64E-C84B6255AE3E Q37043763-1FBC4C97-073C-4AD0-80EB-6FE67710DFCD Q37221579-4F6FAFE6-A977-4152-87F9-ACD4DB632FED Q37252482-3AA45115-AC4E-4ED3-84A6-B9BD07FFDD05 Q37531039-A2777C92-A5A1-4143-8B72-06C16881AD76 Q37623389-9CA9A487-2936-49C8-838D-B58194C84806

P2860

Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation

http://www.wikidata.org/entity/Q36907832

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

2013年论文

@zh

2013年论文

@zh-cn

name

Phase 2 study of azacytidine p ...... al tandem duplication mutation

@en

type

label

Phase 2 study of azacytidine p ...... al tandem duplication mutation

@en

prefLabel

Phase 2 study of azacytidine p ...... al tandem duplication mutation

@en

P1433

Q36907832-DDB658D7-A197-4796-989A-2543AB29E5D3

P1476

Q36907832-8D4E5E64-BFAD-4613-892F-BC38BA95C0A5

P2093

Q36907832-0CD6D12A-F5E8-4430-9609-AB7A5C6652AB

Q36907832-19D8165B-0212-494D-8C0F-E2705B373380

Q36907832-2718ACC8-92A0-4E61-8983-DB21B9E579C1

Q36907832-2D60231B-2E6E-4142-8ADB-A60860CE397F

Q36907832-610B71E9-D042-4A37-BBC6-68A0E0597468

Q36907832-7B936DEB-4FB5-4935-993A-ED42C5267C00

Q36907832-81E7493A-264C-4FFD-B52B-A9053D9EF3EB

Q36907832-B612882B-5A8A-4D38-A6DE-FFE9A5F5987A

Q36907832-DBA8293E-426C-4324-8C87-BF124FFE53B9

Q36907832-F065B407-2416-45AD-A31F-D6CDB3B7C109

P2860

Q36907832-042DBB6B-059E-4503-94F2-941332320685

Q36907832-05B8EEA8-B88B-4309-A425-2F463D05F137

Q36907832-06BA3939-6216-444E-A415-41CC86D0E7FA

Q36907832-0B9924EC-9033-46F0-A375-60B078772676

Q36907832-0D655F9C-AD3B-45A4-8338-688E248562EB

Q36907832-10B87ABC-E56D-4239-9FE4-5498F75631A7

Q36907832-11767A2A-6920-41D8-A407-7183784E5A16

Q36907832-272865C5-40F7-4B24-9E7F-EBFDA33999DD

Q36907832-2E471AE3-874C-4D48-B7AE-4F5F1C460793

Q36907832-38482311-9B56-401F-8419-3EC3F440CB10

P304

Q36907832-D8A582C2-4551-4664-8CD9-4212E2944BA9

P31

Q36907832-3C3B3A6C-8762-45CF-B2B2-25770C616315

P356

Q36907832-471791F8-ECE0-4C6E-AEE1-EEFB739DF999

P407

Q36907832-DF7D243C-2E94-48AA-943B-358DA8169F2B

P433

Q36907832-78225408-C4A8-4BB2-9478-F76B2CF4C819

P478

Q36907832-9A2FADEF-75C3-4002-964D-A3A3014106BB

P50

Q36907832-0818D1DD-47D8-4A47-9787-D0DC624E8C5E

Q36907832-111A6F3D-7F95-4270-8800-0D54E07FFCCC

Q36907832-37D49892-490B-4E2E-863F-726FEF1121A6

Q36907832-4800D1A7-E93C-42AE-B124-5AE785BA6050

Q36907832-7FAFEC8D-1451-45D6-B6B1-BD94E675D8EE

Q36907832-8C75BDAB-1C74-4CF2-9905-D7E97F3BCA55

Q36907832-A890FDDE-4F7B-499A-9D1E-C6C8861189DD

Q36907832-AB3AE117-DC01-4A4B-A14A-F78028C46093

Q36907832-E0AAA3AE-4FA4-42CD-BFEC-DDFE0C226084

Q36907832-EC05ED55-F003-4DDF-8F6D-13A78C98EE71

P577

Q36907832-6974171E-5FFE-49F9-BD71-6E6E027779B0

P698

Q36907832-8884545B-C4EE-4535-8080-0D424E5C9CD8

P921

Q36907832-D1F3F745-2D07-4C2B-BE14-95F05B9A28AA

P932

Q36907832-84AF4E39-6FA4-4FA6-A1C0-42E04E967366

P356

BLOOD-2013-01-480228

P1433

P1476

Phase 2 study of azacytidine p ...... al tandem duplication mutation

@en

P2093

Aziz Nazha

http://www.w3.org/2001/XMLSchema#string

Jan Burger

http://www.w3.org/2001/XMLSchema#string

Mark Levis

http://www.w3.org/2001/XMLSchema#string

Mary Ann Richie

http://www.w3.org/2001/XMLSchema#string

Michael R Grunwald

http://www.w3.org/2001/XMLSchema#string

Michelle A Rudek

http://www.w3.org/2001/XMLSchema#string

Mona Lisa Alattar

http://www.w3.org/2001/XMLSchema#string

Naval Daver

http://www.w3.org/2001/XMLSchema#string

Sara Dellasala

http://www.w3.org/2001/XMLSchema#string

Trivikram Rajkhowa

http://www.w3.org/2001/XMLSchema#string

P2860

Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-alpha (C/EBPalpha), in acute myeloid leukemia

Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia.

Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia.

Sorafenib treatment of FLT3-ITD(+) acute myeloid leukemia: favorable initial outcome and mechanisms of subsequent nonresponsiveness associated with the emergence of a D835 mutation.

Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia.

Compassionate use of sorafenib in FLT3-ITD-positive acute myeloid leukemia: sustained regression before and after allogeneic stem cell transplantation

FLT3 as a therapeutic target in AML: still challenging after all these years

CCAAT/enhancer binding protein alpha is a regulatory switch sufficient for induction of granulocytic development from bipotential myeloid progenitors

Patterns of molecular response to and relapse after combination of sorafenib, idarubicin, and cytarabine in patients with FLT3 mutant acute myeloid leukemia

A pharmacodynamic study of sorafenib in patients with relapsed and refractory acute leukemias

P304

4655-4662

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2013-01-480228

http://www.w3.org/2001/XMLSchema#string

P407

P433

23

http://www.w3.org/2001/XMLSchema#string

P478

121

http://www.w3.org/2001/XMLSchema#string

P50

Jorge Eduardo Cortes

Hagop Kantarjian

Gautam Borthakur

Guillermo Garcia-Manero

Marina Konopleva

Michael Andreeff

P577

2013-04-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23613521

http://www.w3.org/2001/XMLSchema#string

P921

P932

3674666

http://www.w3.org/2001/XMLSchema#string